<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01290510</url>
  </required_header>
  <id_info>
    <org_study_id>TCHY106Tendon-2010-08</org_study_id>
    <nct_id>NCT01290510</nct_id>
  </id_info>
  <brief_title>Hyaluronan in the Treatment of Painful Tendinopathy</brief_title>
  <official_title>Hyaluronan in the Treatment of Painful Tendinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TRB Chemedica AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TRB Chemedica AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy and safety of TCHY106 (2%
      hyaluronan) in the treatment of painful tendinopathy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Visual Analogue Scale of pain (VAS; 100 millimetres (mm)) on day 35</measure>
    <time_frame>Baseline and Day 35</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale of pain (VAS; 100 mm) on day 7</measure>
    <time_frame>On Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale of pain (VAS; 100 mm) on day 90</measure>
    <time_frame>On Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters at baseline</measure>
    <time_frame>At baseline</time_frame>
    <description>Redness
Warmth
Swelling
Tenderness on palpation
Crepitus on motion
Accumulation of tissue fluid
Measured by 5-point scale, ranking from 'none' to 'extreme' intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters on day 7</measure>
    <time_frame>On Day 7</time_frame>
    <description>Redness
Warmth
Swelling
Tenderness on palpation
Crepitus on motion
Accumulation of tissue fluid
Measured by 5-point scale, ranking from 'none' to 'extreme' intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters on day 35</measure>
    <time_frame>On Day 35</time_frame>
    <description>Redness
Warmth
Swelling
Tenderness on palpation
Crepitus on motion
Accumulation of tissue fluid
Measured by 5-point scale, ranking from 'none' to 'extreme' intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters on day 90</measure>
    <time_frame>On Day 90</time_frame>
    <description>Redness
Warmth
Swelling
Tenderness on palpation
Crepitus on motion
Accumulation of tissue fluid
Measured by 5-point scale, ranking from 'none' to 'extreme' intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire at baseline</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire on day 7</measure>
    <time_frame>On Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire on day 35</measure>
    <time_frame>On Day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire on day 90</measure>
    <time_frame>On Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's and investigator's global evaluation of study-relevant tendon complaints on day 7</measure>
    <time_frame>On Day 7</time_frame>
    <description>Measured by Clinical Global Impression (CGI) 7-point scale, ranking from 'very much improved' to 'very much worse' condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's and investigator's global evaluation of study-relevant tendon complaints on day 35</measure>
    <time_frame>On Day 35</time_frame>
    <description>Measured by Clinical Global Impression (CGI) 7-point scale, ranking from 'very much improved' to 'very much worse' condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's and investigator's global evaluation of study-relevant tendon complaints on day 90</measure>
    <time_frame>On Day 90</time_frame>
    <description>Measured by Clinical Global Impression (CGI) 7-point scale, ranking from 'very much improved' to 'very much worse' condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of test product-related Adverse Events</measure>
    <time_frame>Up to Day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Tendinopathy</condition>
  <arm_group>
    <arm_group_label>hyaluronic acid sodium salt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>hyaluronic acid sodium salt</intervention_name>
    <description>Two injections of 2 % (40 milligrams (mg) / 2 millilitres (ml)) hyaluronan in weekly interval.</description>
    <arm_group_label>hyaluronic acid sodium salt</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients between 18 and 75 years of age and good general health
             condition.

          -  Signed written informed consent.

          -  Painful tendinopathy since ≥ 6 weeks.

          -  Pain according to Visual Analogue Scale (VAS; 100 millimetres (mm)) ≥ 40 mm.

          -  Ensured compliance of subjects for study period.

        Exclusion Criteria:

          -  Treatment with any investigational product within 4 weeks prior to study entry.

          -  Patients with known hypersensitivity to the products (that is active compound and
             excipients) or any component or procedure used in the study.

          -  Severe intercurrent illness (for example: uncontrolled diabetes mellitus, peripheral
             neuropathy), which in the opinion of the investigator, may put the patient at risk
             when participating in the study, or affect the patient's ability to take part in the
             study.

          -  Concomitant disease at study relevant site influencing study evaluation.

          -  List of diseases or characteristics judged by the investigator to be incompatible with
             the assessments and/or procedures for the study evaluation.

          -  List of concomitant medications not allowed.

          -  Patients treated with: systemic and/or local steroids within the last 4 weeks,
             immunosuppressive drugs within the last 3 months, repeated use of non-steroidal
             anti-inflammatory drugs (NSAIDs) within the last week or occasional use within 24
             hours.

          -  Recent history of drug and/or alcohol abuse (within the last 6 months).

          -  List of contra-indications to the treatment.

          -  Pregnant or lactating females.

          -  Fertile women who do not accept the consistent and correct use of highly effective
             methods of birth control defined as implants, injectables, combined oral
             contraceptives, intrauterine devices (IUDs), sexual abstinence or vasectomised partner
             during the treatment period and the first 4 weeks follow-up period.

          -  Subjects unable to understand informed consent or having a high probability of non
             compliance to the study procedures and or non completion of the study according to
             investigator's judgement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nils Lynen, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orthopädische Gemeinschaftspraxis Elisengalerie, Aachen (Germany)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zentrum für Orthopädie und Sportmedizin München</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopädische Gemeinschaftspraxis Elisengalerie</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52062</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2011</study_first_submitted>
  <study_first_submitted_qc>February 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2011</study_first_posted>
  <last_update_submitted>September 21, 2011</last_update_submitted>
  <last_update_submitted_qc>September 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tendinopathy</keyword>
  <keyword>hyaluronan</keyword>
  <keyword>tendon</keyword>
  <keyword>hyaluronic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tendinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

